Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Breast Neoplasms 2Urologic Diseases 1Taste Disorders 1Renal Insufficiency 1Recurrence 1Malnutrition 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Kidney Neoplasms 1Kidney Diseases 1Intracranial Germ Cell Tumors 1Hypothermia 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Ice × Clear all
NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated
56 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT02856997 2016-08-05

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
35 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡